



November 14, 2023

The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
PhirozeJeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir

Subject: **Outcome of Board Meeting.**

This has reference to our letter dated 06th November 2023.

At the meeting of the Board of Directors of the company held on Tuesday 14th November 2023, the following decisions were taken:

1. Un- Audited Financial Results (standalone and consolidated) for the quarter and half year ended 30.09.2023. (Attached).
2. Limited Review Report (standalone and consolidated) for the Quarter and half year ended 30.09.2023. (Attached).
3. The Board considered and approved the appointment of M/s. Vasavi & Co, Chartered Accountants as Statutory Auditors of the Company for a period of Five years from the financial year 2023-24 upto-2027-2028, subject to the approval of members in the ensuing annual general meeting.
4. The Board considered and approved of M/s.Manisha Dubey, as internal auditor of the Company for financial year 2023-24.
5. The Board considered and approved the Notice of the 33rd Annual General meeting for the Financial Year 2022-2023 and other related matters thereto.
6. The Board considered and approved Directors' Report and the annexure thereon for the Financial Year 2022-2023.
7. It was decided to hold the 33rd Annual General Meeting on Saturday the 30th December 2023 at IST through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") at 10.00 A.M. (IST).



TRANSGENE
BIOTEK LIMITED
INNOVATING. FOR LIFE.

8. The Register of Members and Share Transfer Books of the Company will remain closed from Tuesday the 26th December 2023 to Friday the 29th December, 2023 (both days inclusive).

The meeting commenced at 11.00 A.M and concluded at 11.50 A.M.

This is for your information and records.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED

DR K KOTESWARA RAO
MANAGING DIRECTOR
DIN NO:02287235

Encls: as above



Limited Review Report

To,
The Board of Directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotek Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 30 Sep 2023 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities

Name of the entity	Relationship
1. Transgene Biotek HK Limited	Subsidiary
2. PerOral Bio Private Limited	Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph



below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed or that it contains any material misstatement.

6. We did not review the interim financial results of two subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 Sep 2023, as considered in the consolidated unaudited financial results.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S



ManishaDubey
Proprietor
M No.212664
Place: Hyderabad
Date: 14.11.2023

Unique Document Identification Number (UDIN) for this document is 23212664BGZHLT5244




Limited review report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 30 Sep 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting". - ("IndAS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S



ManishaDubey
Proprietor
M No.212664
Place: Hyderabad
Date: 14.11.2023



TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

(In Rs.)

Standalone Statement of assets and liabilities

PARTICULARS	As at 30 September 2023	As at 31 March 2023
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	171,40,236	175,65,982
(b) Right of Use Assets	0	0
(c) Capital work-in-progress	0	0
(d) Investment Properties	0	0
(e) Goodwill	0	0
(f) Other intangible assets	468,82,617	469,18,565
(g) Intangible assets under development	186,76,633	186,76,633
(h) Biological Assets Other Than Bearer Plants	0	0
(i) Financial assets	0	0
(i) Investments	9,50,150	10,50,140
(ii) Trade Receivables	0	0
(iii) Loans	2302,04,250	2302,04,250
(iv) Other Financial Assets	0	0
(j) Deferred Tax Assets (Net)	0	0
(k) Other non-current assets	13,96,810	15,05,437
SUB-TOTAL	3152,50,696	3159,21,007
CURRENT ASSETS		
(a) Inventories	3,39,043	3,37,603
(b) Financial assets	0	0
(i) Investments	0	0
(ii) Trade Receivables	0	0
(iii) Cash and cash equivalents	1,04,382	29,824
(iv) Bank Balances other than (iii) above	699	699
(v) Loans	0	0
(vi) Other Financial Assets	0	0
(c) Current Tax Assets (Net)	0	0
(d) Other current assets	90,49,802	84,88,786
SUB-TOTAL	94,93,926	88,56,912
Non-Current Assets Classified as Held for Sale	-	-
TOTAL ASSETS	3247,44,622	3247,77,919

EQUITY AND LIABILITIES	As at 30 September 2023	As at 31 March 2023
EQUITY		
Equity share capital	7577,00,000	7577,00,000
Other equity	-8224,94,653	-8197,53,891
SUB-TOTAL	(647,94,653)	(620,53,891)
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	501,49,282	495,03,606
(ii) Trade Payable	0	0
(iii) Other financial liabilities	0	0
(b) Provisions	2302,04,250	2302,04,250
(c) Deferred tax liabilities (net)	0	0
(d) Other non-current liabilities	26,30,823	35,07,763
SUB-TOTAL	2829,84,355	2832,15,619
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	855,06,358	816,94,725
(ii) Trade payables	20,42,752	22,86,700
(iii) Other financial liabilities	0	0
(b) Provisions	181,88,366	182,06,660
(c) Other current liabilities	8,17,444	14,28,106
(d) Current tax liabilities (net)	0	0
SUB-TOTAL	1065,54,920	1036,16,191
TOTAL EQUITY AND LIABILITIES	3247,44,622	3247,77,919
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 14-11-2023

Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2023

(In Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Audited)	31.03.2023 (Audited)
1	Revenue from operations	4,50,000	9,98,710	-	5,50,847
2	Other income (net)	4,38,470	4,38,470	4,38,470	17,53,880
3	Total income (1 + 2)	8,88,470	14,37,180	4,38,470	23,04,727
4	EXPENSES				
	Cost of materials consumed	1,440	-	4,894	54,546
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	6,08,617
	Employee benefits expense	7,93,179	7,86,312	7,45,857	30,37,608
	Finance costs	3,22,838	3,22,838	4,53,410	18,13,638
	Depreciation and amortisation expense	2,30,847	2,30,847	123,77,921	495,00,842
	Other expenses	8,65,934	14,12,187	45,51,962	73,73,161
	Total expenses	22,14,238	27,52,184	181,34,044	623,88,413
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(13,25,768)	(13,15,004)	(176,95,574)	(600,83,686)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(13,25,768)	(13,15,004)	(176,95,574)	(600,83,686)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(13,25,768)	(13,15,004)	(176,95,574)	(600,83,686)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(13,25,768)	(13,15,004)	(176,95,574)	(600,83,686)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.02)	(0.02)	(0.23)	(0.79)
	Diluted (Rs.)	(0.02)	(0.02)	(0.23)	(0.79)

Notes:

- It has been reported that NiedlFree has concluded Canine Insulin Study studies demonstrating excellent results on all parameters.
- As informed by NiedlFree, they are continuing the interactions with various companies for formulating the third-party molecules for delivery through oral route apart from ongoing talks on strategic deals.
- Next date for SAT hearing is fixed for 22nd November. 2023.
- The management has been informed by the Swiss legal team that the process of claims against Investec Bank has been initiated.
- No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th November 2023

For TRANSGENE BIOTEK LIMITED

Dr.K.Koteswara Rao
Managing Director

 Date: 14-11-2023
 Place:Hyderabad

TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollaram, Sangareddy DISTRICT.
Standalone Statement of Cash Flows for the year ended 30-09-2023

(In Rs.)

Particulars	For the year ended September 30, 2023		For the year ended March 31, 2023	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(26,40,772)		(600,83,686)
<u>Adjustments for :</u>				
Depreciation and amortisation expense	4,61,694		495,00,842	
Finance costs	6,45,676		18,13,638	
Amortisation of government grant	(8,76,940)		(17,53,880)	
Supplier Advances Written off	-		-	
Bad debts written off	-		-	
Profit or loss on sale of Fixed asset	-		-	
Other Non cash Expenses	-		-	
Operating profit before working capital changes		(24,10,342)		(105,23,085)
<u>Changes in working capital:</u>				
<u>Adjustments for (increase) / decrease in operating assets:</u>				
Trade receivables			-	
Other non-current assets	1,08,627		-	
Other Current assets	(5,61,016)		(26,85,728)	
Inventories	(1,440)		6,08,617	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>				
Trade payables	(2,43,948)		2,58,940	
Provision (CL)	(18,294)		40,58,984	
Borrowing (CL)	38,11,633		92,28,725	
Other financial liabilities				
Other current liabilities	(6,10,662)		(9,44,148)	
Provison (NCL)			-	
Cash generated from operations		74,558		2,305
Net income tax paid		-		-
Net cash flow from operating activities (A)		74,558		2,305
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances			(14,661)	
Investments	-		-	
Proceeds from sale of fixed assets			(1,08,349)	
Net cash (used in) / flow from investing activities (B)		-		(1,23,010)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				-
Net cash flow (used in) financing activities (C)		-		-
Net (decrease) in Cash and cash equivalents (A+B+C)		74,558		(1,20,705)
Cash and cash equivalents at the beginning of the year		30,522		1,51,227
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
		-		-
Cash and cash equivalents at the end of the year		1,05,080		30,522

For and on behalf of the Board of Directors
M/s TRANSGENE BIOTEK LIMITED



Dr.K K Koteswara Rao
Chairman & Managing Director
DIN:02287235

Place: Hyderabad
Date:14-11-2023



TRANSGENE BIOTEK LIMITED

69 & 70, IDA Bollaram, Sangareddy District - 502325, Telangana

CIN NO: L85195TG1990PLC011065

(In Rs.)

Consolidated Statement of assets and liabilities

PARTICULARS	As at 30 September 2023	As at 31 March 2023
ASSETS		
NON-CURRENT ASSETS		
(a) Property, plant and equipment	171,40,236	175,65,982
(b) Right of Use Assets	0	0
(c) Capital work-in-progress	0	0
(d) Investment Properties	0	0
(e) Goodwill	0	0
(f) Other intangible assets	468,82,617	469,18,565
(g) Intangible assets under development	186,76,633	186,76,633
(h) Biological Assets Other Than Bearer Plants	0	0
(i) Financial assets	0	0
(i) Investments	9,50,150	9,50,150
(ii) Trade Receivables	0	0
(iii) Loans	13290,24,004	13290,24,004
(iv) Other Financial Assets	0	0
(j) Deferred Tax Assets (Net)	0	0
(k) Other non-current assets	13,96,810	15,05,437
SUB-TOTAL	14140,70,450	14146,40,771
CURRENT ASSETS		
(a) Inventories	3,39,043	3,37,603
(b) Financial assets	0	0
(i) Investments	0	0
(ii) Trade Receivables	84,460	84,460
(iii) Cash and cash equivalents	1,04,382	29,824
(iv) Bank Balances other than (iii) above	699	699
(v) Loans	0	0
(vi) Other Financial Assets	0	0
(c) Current Tax Assets (Net)	0	0
(d) Other current assets	90,49,802	84,88,786
SUB-TOTAL	95,78,386	89,41,372
Non-Current Assets Classified as Held for Sale	-	-
TOTAL ASSETS	14236,48,836	14235,82,143

EQUITY AND LIABILITIES	As at 30 September 2023	As at 31 March 2023
EQUITY		
Equity share capital	7577,00,000	7577,00,010
Other equity	-6467,26,478	-6440,11,997
SUB-TOTAL	1109,73,522	1136,88,013
LIABILITIES		
NON-CURRENT LIABILITIES		
(a) Financial Liabilities		
(i) Borrowings	501,49,282	495,03,606
(ii) Trade Payable	0	0
(iii) Other financial liabilities	0	0
(b) Provisions	11522,13,978	11522,13,978
(c) Deferred tax liabilities (net)	0	0
(d) Other non-current liabilities	26,30,823	35,07,763
SUB-TOTAL	12049,94,083	12052,25,347
CURRENT LIABILITIES		
(a) Financial liabilities		
(i) Borrowings	855,06,358	816,21,006
(ii) Trade payables	20,42,752	22,86,700
(iii) Other financial liabilities	11,26,311	11,26,311
(b) Provisions	181,88,366	182,06,660
(c) Other current liabilities	8,17,444	14,28,106
(d) Current tax liabilities (net)	0	0
SUB-TOTAL	1076,81,231	1046,68,783
TOTAL EQUITY AND LIABILITIES	14236,48,836	14235,82,143
Corporate information and significant accounting policies		
The accompanying notes form an integral part of the Consolidated financial statements		

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 14-11-2023
Place:Hyderabad

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District. IDA Bollaram Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER 2023

(In Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Audited)	31.03.2023 (Audited)
1	Revenue from operations	4,50,000	9,98,710	-	5,50,847
2	Other income (net)	4,38,470	4,38,470	4,38,470	17,53,880
3	Total income (1 + 2)	8,88,470	14,37,180	4,38,470	23,04,727
4	EXPENSES				
	Cost of materials consumed	1,440	-	4,894	54,546
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	6,08,617
	Employee benefits expense	7,93,179	7,86,312	7,45,857	30,37,608
	Finance costs	3,22,838	3,22,838	4,53,410	18,13,638
	Depreciation and amortisation expense	2,30,847	2,30,847	123,77,921	495,00,842
	Other expenses	8,65,934	14,85,906	45,51,962	73,75,461
	Total expenses	22,14,238	28,25,903	181,34,044	623,90,713
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(13,25,768)	(13,88,723)	(176,95,574)	(600,85,986)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(13,25,768)	(13,88,723)	(176,95,574)	(600,85,986)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(13,25,768)	(13,88,723)	(176,95,574)	(600,85,986)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(13,25,768)	(13,88,723)	(176,95,574)	(600,85,986)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.02)	(0.02)	(0.23)	(0.79)
	Diluted (Rs.)	(0.02)	(0.02)	(0.23)	(0.79)

Notes:

- It has been reported that NiedlFree has concluded Canine Insulin Study studies demonstrating excellent results on all parameters.
- As informed by NiedlFree, they are continuing the interactions with various companies for formulating the third-party molecules for delivery through oral route apart from ongoing talks on strategic deals.
- Next date for SAT hearing is fixed for 22nd November. 2023.
- The management has been informed by the Swiss legal team that the process of claims against Investec Bank has been initiated
- No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14th November 2023.

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
 Managing Director

 Date: 14-11-2023
 Place:Hyderabad

TRANSGENE BIOTEK LIMITED

69 & 70, Anrich Industrial Area, Bollarum, SANGAREDDY DISTRICT.
Consolidated Statement of Cash Flows for the year ended 30-09-2023

(In Rs.)

Particulars	For the year ended September 30, 2023		For the year ended March 31, 2023	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit before tax		(27,14,491)		(600,83,686)
<i>Adjustments for :</i>				
Depreciation and amortisation expense	4,61,694		495,00,842	
Finance costs	6,45,676		18,13,638	
Amortisation of government grant	(8,76,940)		(17,53,880)	
Supplier Advances Written off	-		-	
Bad debts written off	-		-	
Profit or loss on sale of Fixed asset	-		-	
Other Non cash Expenses	-		-	
Operating profit before working capital changes		(24,84,061)		(105,23,085)
<i>Changes in working capital:</i>				
<i>Adjustments for (increase) / decrease in operating assets:</i>				
Trade receivables			-	
Other non-current assets	1,08,627		-	
Other Current assets	(5,61,016)		(26,85,728)	
Inventories	(1,440)		6,08,617	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>				
Trade payables	(2,43,948)		2,58,940	
Provision (CL)	(18,294)		40,58,984	
Borrowing (CL)	38,85,352		92,28,725	
Other financial liabilities				
Other current liabilities	(6,10,662)		(9,44,148)	
Provison (NCL)			-	
Cash generated from operations		74,558		2,305
Net income tax paid		-		-
Net cash flow from operating activities (A)		74,558		2,305
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances			(14,661)	
Investments	-		-	
Proceeds from sale of fixed assets			(1,08,349)	
Net cash (used in) / flow from investing activities (B)		-		(1,23,010)
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares				
Finance costs				
Proceeds from Borrowings				
Payment of Borrowing				-
Net cash flow (used in) financing activities (C)		-		-
Net (decrease) in Cash and cash equivalents (A+B+C)		74,558		(1,20,705)
Cash and cash equivalents at the beginning of the year		30,522		1,51,227
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
		-		-
Cash and cash equivalents at the end of the year		1,05,080		30,522

For and on behalf of the Board of Directors

M/s TRANSGENE BIOTEK LIMITED



Dr. K K Koteswara Rao

Chairman & Managing Director

DIN:02287235

Place: Hyderabad

Date: 14-11-2023